ArticlePloS one2025
Evaluation of Sub-acute toxicity and safety profile of Charmagaz seed oil in rats.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Charmagaz seed oil (CSO), derived from Cucurbitaceae family, and is a traditional mix of four different seeds: pumpkin, cucumber, watermelon, and musk melon. Widely utilized in Asia, this blend is considered as a brain tonic and a nutritional powerhouse. Despite its significant ethno medicinal value, the potential toxicity and safety of this combination oil have not been scientifically documented. Therefore, the current study was conducted to assess the sub-acute toxicity of Charmagaz seed oil in rat model for the assessment of its safety profile. For acute oral toxicity CSO was given at doses of 50, 500, and 5000 mg/kg orally over 28 days in rats. No evidence of toxicity was observed in animals when acutely exposed to CSO, implying that the LD50 is higher than 5000 mg/kg body weight. Cell viability assay revealed that Charmagaz oil is relatively non-toxic, showing an inhibition rate below 50% following 24 and 48-hour exposures. In the Brine Shrimp bioassay, oil demonstrated no cytotoxic effects, unlike the standard cytotoxic drug Etoposide, which resulted in 70% mortality at a 7.5 μg/ml concentration. No treatment-related toxicity or death was seen in any of the animals receiving dosages of 500 and 5000 mg/kg during the course of the 28-day study period, according to sub-acute oral toxicity tests. Additionally, no significant alterations (p > 0.05) were detected in hematological or biochemical parameters across the dosed groups. The administration of Charmagaz seed oil led to a modest elevation in high-density lipoprotein cholesterol, likely due to its polyunsaturated fatty acids content. Since the liver is a major organ involved in lipid metabolism hence, histopathological analysis was conducted to determine the effects of Charmagaz oil on hepatic tissues. The analysis revealed a positive correlation with biochemical results from liver function enzyme tests. Thus, this study provides evidence suggesting the safety of Charmagaz oil consumption at doses up to 5000 mg/kg.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.